

DAFTAR PUSTAKA

1. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. *Current opinion in rheumatology*. 2018;30(2):144–50.
2. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. *Ann Rheum Dis*. 2023;82(3):351–6.
3. Hamijoyo L, Candrianita S, Rahmadi AR, Dewi S, Darmawan G, Suryajaya BS, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. *Lupus*. 2019;28(13):1604–9.
4. Chavele KM, Ehrenstein MR. Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. Vol. 585, *FEBS Letters*. 2011;3603–10.
5. Sumariono, Kalim H, Setyohadi B, Hidayat R, Najirman, Hamikoyo L, et al. Diagnosis dan pengelolaan SLE 2019. Rekomendasi Perhimpunan Reumatologi Indonesia Diagnosis dan pengelolaan Lupus Eritematosus Sistemik. 2019;1:129.
6. Bagga A, Sinha A. Symposium on steroid therapy pulse steroid therapy. *Indian J Pediatr*. 2008;75.
7. Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. 2007;16:387–93

8. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis.* 2023;83(1):15–29.
9. Ingawale DK, Mandlik SK. New insights into the novel anti-inflammatory mode of action of glucocorticoids. Vol. 42, *Immunopharmacology and Immunotoxicology*. Taylor and Francis Ltd. 2020;59–73.
10. Aliska G. Hubungan antara reseptor glukokortikoid dengan ekspresi ikb α dan GILZ serta faktor yang memengaruhi respons terapi kortikosteroid pada pasien covid-19 derajat sedang-berat. Universitas Indonesia Library. 2023
11. Lekva T, Bollerslev J, Kristo C, Olstad OK, Ueland T, Jemtland R. The Glucocorticoid-Induced Leucine Zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis. *Journal of Clinical Endocrinology and Metabolism.* 2010;95(1):246–55.
12. Malaise O, Relic B, Charlier E, Zeddou M, Neuville S, Deroyer C, et al. Glucocorticoid-induced leucine zipper (GILZ) is involved in glucocorticoid-induced and mineralocorticoid-induced leptin production by osteoarthritis synovial fibroblasts. *Arthritis Res Ther.* 2016;18(1):102-16
13. Aguilar DC, Strom J, Xu B, Kappeler K, Chen QM. Expression of glucocorticoid-induced leucine zipper (GILZ) in cardiomyocytes. *Cardiovasc Toxicol.* 2013;13(2):91–9.
14. Dankers W, Northcott M, Bennett T, D'Cruz A, Sherlock R, Gearing LJ, et al. Type 1 interferon suppresses expression and glucocorticoid induction of

- glucocorticoid-induced leucine zipper (GILZ). *Front Immunol.* 2022;23(1);13-22.
15. Ronchetti S, Ayroldi E, Ricci E, Gentili M, Migliorati G, Riccardi C. A glance at the use of glucocorticoids in rare inflammatory and autoimmune diseases: still an indispensable pharmacological tool? Vol. 11, *Frontiers in Immunology*. Frontiers Media S.A. 2021.
 16. Suarjana I. *Imunopatogenesis lupus eritematosus sistemik*. Buku Ajar Ilmu Penyakit Dalam Edisi VI. Balai Penerbit FKUI. 2014
 17. Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, Van Vollenhoven R, et al. Systemic lupus erythematosus. *Nat Rev Dis Primers.* 2016;16:21-9.
 18. Celhar T, Fairhurst AM. Modelling clinical systemic lupus erythematosus: similarities, differences and success stories. Vol. 56, *Rheumatology (Oxford, England)*. 2017;88–99.
 19. Hahn BH. Systemic lupus erythematosus. In: *Harrison's Principles of Internal Medicine*. 20th ed. Mc Graw Hill. 2019.
 20. Miguel B, Celeste M, Teresa M. Pathogen strategies to evade innate immune response: a signaling point of view. *Protein Kinases.* 2012.
 21. Galarza-Maldonado C, Kourilovitch MR, Molineros JE, Cardiel MH, Zurita L, Soroka NF, et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. *Autoimmun Rev.* 2010;10(2):108–11.
 22. Humrich JY, Spee-Mayer C Von, Siegert E, Alexander T, Hiepe F, Radbruch A, et al. Rapid induction of clinical remission by low-dose interleukin-2 in a

- patient with refractory SLE. Vol. 74, *Annals of the Rheumatic Diseases*. BMJ Publishing Group. 2015;791–2.
23. Williams DM. Clinical pharmacology of corticosteroids. *Respir Care*. 2018;1;63(6):655–70.
24. Katzung BG. *Basic & Clinical Pharmacology* [Internet]. Available from: <http://www.usdoj.gov/dea/pubs/scheduling.html>
25. Bertias G, Askanase A, Doria A, Saxena A, Vital EM. A path to glucocorticoid stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus. *Rheumatology*. 2024
26. Ayroldi, E., Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. *FASEB J*. 2017;23;3649–58.
27. Nataraja C, Morand E. Systemic glucocorticoid therapy for SLE. In: *Dubois' Lupus Erythematosus and Related Syndromes*. Elsevier. 2018;661–72.
28. Annamayra A, Ekawardhani S, Rahmadi AR, Hamijoyo L, Atik N. The molecular mechanism of corticosteroids for Systemic Lupus Erythematosus Patient's treatment and its adverse effects. *Systematic Reviews in Pharmacy*. 2020;11(2);249–54.
29. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Vol. 32, *Seminars in Arthritis and Rheumatism*. W.B. Saunders. 2003;370–7.
30. Porta S, Danza A, Saavedra M, Carlomagno A, Goizueta M, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. *Journal of Clinical Medicine*. MDPI. 2020;9;1-13

31. Dhistiarine P. Pengaruh kortikosteroid pulse dose terhadap jumlah sel limfosit T cd4+, kadar sel T regulator, interleukin-2 dan nilai MEX-SLEDAI pada pasien lupus eritematosus sistemik. 2019
32. Tselios K, Sarantopoulos A, Gkoukouras I, Boura P. The influence of therapy on CD4+CD25 high FOXP3+ regulatory T cells in systemic lupus erythematosus patients: A prospective study. *Scand J Rheumatol.* 2015;44(1):29–35
33. Liu T, Zhang L, Joo D, Sun SC. NF- κ B signaling in inflammation. *Signal Transduction and Targeted Therapy.* Springer Nature. 2017(2)
34. Bereshchenko O, Migliorati G, Bruscoli S, Riccardi C. Glucocorticoid-induced leucine zipper : a novel anti-inflammatory molecule. *Front. Pharmacol.* 2019;10:308
35. Miceli L, Sherlock R, Hall P, Cheang L, D’Cruz A, Bannet T, et al. A novel E3 ligase of GILZ: validation of a steroid-sparing therapeutic target in SLE (abstract). *Arthritis Rheumatol.* 2024; 76 (suppl 9)
36. Nataraja C, Dankers W, Flynn J, Lee JPW, Zhu W, Vincent FB, et al. GILZ regulates the expression of pro-inflammatory cytokines and protects against end-organ damage in a model of lupus. *Front Immunol.* 2021;12:114-25
37. Sun J, Lyu T, Chen Z, Lian C, Liu Su, Shao Ti, et al. Methylprednisolone pulse therapy promotes the differentiation of regulatory T cells by inducing the apoptosis of CD4+ T cells in patients with systemic lupus erythematosus. *Clinical Immunology.* 2022;241:112-21
38. Lailani M, Aliska G, Putra A. The profile of glucocorticoid-induced leucine zipper protein in sepsis patient with comorbidity. *ACPE.* 2024.

39. Mona Z, Julizar, Elvira D, Abdiana, Liza RG, Suharti N. Kualitas hidup pasien lupus eritematosus sistemik berdasarkan LupusQoL di RSUP Dr. M. Djamil Padang. *JIKESI (Jurnal Ilmi Kesehatan Indonesia)*. 2025;75-85
40. Adnan, Alfriani VA. Profile and clinical outcomes of drug therapy for systemic lupus erythematosus patients in Yogyakarta health services. *Jurnal Kesehatan Bakti Tunas Husada*. 2023;23;20-38
41. Raveinal, Elvira D, Delfin M. Analysis of serum levels of B cell activating factor and soluble B cell activating factor receptor with disease activity in systemic lupus erythematosus. *Universa Medicina*. 2025;44:181-189
42. Kim JW, Kim HA, Suh CH, Jung JY. Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. *Front. Med*. 9:906475. 2022
43. Yuliasih. Perkembangan patogenesis dan tatalaksana sytemic lupus erythematosus. Airlangga University Press. 2020;978-602-473-630-3
44. Hamijoyo L, Candrianita S, Rahmadi AR, Darmawan G, Suryajaya B, Rainy NR, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia : a cohort registry from an Indonesia-based tertiary referral hospital. 2019
45. Guéry JC. Why is systemic lupus erythematosus more common in women?. *Joint Bone Spine*. 2019;86(3):297 – 9.
46. Bertsias G, Cervera R. Boumpas. Systemic lupus erythematosus : pathogenesis and clinical features. In *EULAR Textbook on Rheumatic Diseases*. 2012:476-505

47. Angel A, Vaillant J, Goyal A, Varacallo MA. Systemic lupus erythematosus. National Libarry of Medicine. 2023
48. Bashal F. Hematological disorders in patients with systemic lupus erythematosus. *Open Rheumatol J*. 2013;7:87–95.
49. Tjan B, Kambayana G, Kurniari PK. Gambaran profil systemic lupus erythematosus (SLE) dan lupus nefritis di rumah sakit umum pusat sanglah. *Jurnal Penyakit Dalam Udayana*. 2022;2;31-35
50. Shin J, Lee KH, Park S, Wang JW, Kim HJ, Song K. systemic lupus erythematosus and lung involvement : a comprehensive review. *Journal of Clinical Medicine*. 2022;11:6714
51. Ruiz-Irastorza G, Khamashta M. Cardiopulmonary disease in SLE. In: Dubois' lupus erythematosus and related syndromes. 8th ed. Elsevier Inc.; 2013:473–85.
52. Putra SD, Ardisasmita MN, Hamijoyo L. Neuropsychiatric manifestation screening among systemic lupus erythematosus patients in hasan sadikin general hospital bandung. *Indonesian Journal of Rheumatology*. 2017;9:18-22
53. Mohammadi S, Ebadpour MR, Sedighi S, Saeedi M, Memarian A. Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus. *Clin Rheumatol*. 2017;36:1765-1772
54. Alharbi LK, Al-Homood A, Binammar AA, Almuhareb NM. Organ damage and its associated factors in systemic lupus erythematosuspatients : a retrospective cohort studies. *J Clin Med Res*. 2025;17(1): 35-43

55. Arevalo AM, Quaye A, Rojas LC, Poole BD, Santamaria DB, Freitas CM. Synthetic pharmacotherapy for systemic lupus erythematosus: potential mechanisms of action, efficacy, and safety. *Medicina*. 2023;59
56. Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. *Ther Adv Musculoskel Dis*. 2022;14:1-25
57. Pan L, Liu J, Liu C, Guo L, Yang S. Intermittent pulses of methylprednisolone with low-dose prednisone attenuate lupus symptoms in B6.MRL-Faslpr/J mice with fewer glucocorticoid side effects. *Biomedicine & Pharmacotherapy*. 2024;117138
58. Sun JL, Lyu T, Chem Z, Liu S, Shao T, Zhang S et al. Methylprednisolone pulse therapy promotes the differentiation of regulatory T cells by inducing the apoptosis of CD4⁺ T cells in patients with systemic lupus erythematosus. *Clin Immunol*. 2022;241:109079
59. Evangelopoulus ME, Ansari NN, Kassi E, Papadopoulou A, Moutsatsou. Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response. *Nature Portofolio*. 2021;11:19462
60. Nataraja C, Dankers W, Flynn J, Lee PW, Zhu W, Vincent F. GILZ regulates the expression of pro-inflammatory cytokines and protects against end-organ damage in a model of lupus. *Frontiers in Immunology*. 2021;12:652800
61. Ayroldi E, Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new player in glucocorticoid anti-inflammatory and immunosuppressive activity. *Trends Immunol*. 2009;30(6): 269–276.

62. Adamio F. Cloning and expression of glucocorticoid-induced leucine zipper (GILZ), a glucocorticoid-induced gene involved in T lymphocyte regulation. *Science*. 2007;276(5319):1326–1330.
63. Beaulieu E, Morand EF. GILZ as a mediator of glucocorticoid action in immune cells. *Mol Cell Endocrinol*. 2011;335(1):87–95.
64. Paramaiswari A, Kertia N, Intansari U, Nugroho DB. Predicting systemic lupus erythematosus disease activity index 2000 (sledai 2k) score after pulse dose methylprednisolone in severe systemic lupus erythematosus. *F1000 Research*. 2003;12:992
65. Porta A, Danza A, Saavedra MA, Carlomagno A, Goizueta M, Vivero F et al. Glucocorticoid in systemic lupus erythematosus, ten questions and some issues. *Journal of Clinical Medicine*. 2009 ;9:2709
66. Erik J, Idha A, Suryana B, Yulistiani. Megadose methylprednisolone on total lymphocyte count and disease activity in systemic lupus erythematosus. *Folia Medica Indonesiana*. 2015;51:40-44
67. Yao Z, Dubois DC, Almon R, Jusko W. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. *J Pharm Sci*. 2008;97(&):2820-2823
68. Datta S, Sarvetnick. Lymphocyte proliferation in immune-mediated diseases. *Trends Immunol*. 2009;30(9):430-8
69. Ruiz G, Paredes D, Herrero M, Moreno V, Hernandez H, Ruiz L et al. Methylprednisolone pulses and prolonged remission in systemic lupus erythematosus: a propensity score analysis of the longitudinal lupus-cruces-bordeaux inception cohort. *Arthritis Care & Research*. 2024;76(8):1132-38

70. Kartyanto A, Paramaiswari A, Keria N. The relationship between the number of major organ involvement and therapeutic response of pulse dose methylprednisolone in systemic lupus erythematosus patients. *Acta Interna The Journal of Internal Medicine*. 2023;12(1): 40-52

